Department of Anaesthesiology, Intensive Care Medicine and Pain Medicine, University Hospital Münster, Germany.
Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pennsylvania.
JAMA. 2016;315(20):2190-9. doi: 10.1001/jama.2016.5828.
Optimal timing of initiation of renal replacement therapy (RRT) for severe acute kidney injury (AKI) but without life-threatening indications is still unknown.
To determine whether early initiation of RRT in patients who are critically ill with AKI reduces 90-day all-cause mortality.
DESIGN, SETTING, AND PARTICIPANTS: Single-center randomized clinical trial of 231 critically ill patients with AKI Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 (≥2 times baseline or urinary output <0.5 mL/kg/h for ≥12 hours) and plasma neutrophil gelatinase-associated lipocalin level higher than 150 ng/mL enrolled between August 2013 and June 2015 from a university hospital in Germany.
Early (within 8 hours of diagnosis of KDIGO stage 2; n = 112) or delayed (within 12 hours of stage 3 AKI or no initiation; n = 119) initiation of RRT.
The primary end point was mortality at 90 days after randomization. Secondary end points included 28- and 60-day mortality, clinical evidence of organ dysfunction, recovery of renal function, requirement of RRT after day 90, duration of renal support, and intensive care unit (ICU) and hospital length of stay.
Among 231 patients (mean age, 67 years; men, 146 [63.2%]), all patients in the early group (n = 112) and 108 of 119 patients (90.8%) in the delayed group received RRT. All patients completed follow-up at 90 days. Median time (Q1, Q3) from meeting full eligibility criteria to RRT initiation was significantly shorter in the early group (6.0 hours [Q1, Q3: 4.0, 7.0]) than in the delayed group (25.5 h [Q1, Q3: 18.8, 40.3]; difference, -21.0 [95% CI, -24.0 to -18.0]; P < .001). Early initiation of RRT significantly reduced 90-day mortality (44 of 112 patients [39.3%]) compared with delayed initiation of RRT (65 of 119 patients [54.7%]; hazard ratio [HR], 0.66 [95% CI, 0.45 to 0.97]; difference, -15.4% [95% CI, -28.1% to -2.6%]; P = .03). More patients in the early group recovered renal function by day 90 (60 of 112 patients [53.6%] in the early group vs 46 of 119 patients [38.7%] in the delayed group; odds ratio [OR], 0.55 [95% CI, 0.32 to 0. 93]; difference, 14.9% [95% CI, 2.2% to 27.6%]; P = .02). Duration of RRT and length of hospital stay were significantly shorter in the early group than in the delayed group (RRT: 9 days [Q1, Q3: 4, 44] in the early group vs 25 days [Q1, Q3: 7, >90] in the delayed group; P = .04; HR, 0.69 [95% CI, 0.48 to 1.00]; difference, -18 days [95% CI, -41 to 4]; hospital stay: 51 days [Q1, Q3: 31, 74] in the early group vs 82 days [Q1, Q3: 67, >90] in the delayed group; P < .001; HR, 0.34 [95% CI, 0.22 to 0.52]; difference, -37 days [95% CI, -∞ to -19.5]), but there was no significant effect on requirement of RRT after day 90, organ dysfunction, and length of ICU stay.
Among critically ill patients with AKI, early RRT compared with delayed initiation of RRT reduced mortality over the first 90 days. Further multicenter trials of this intervention are warranted.
German Clinical Trial Registry Identifier: DRKS00004367.
对于严重急性肾损伤(AKI)但没有危及生命的患者,最佳开始肾脏替代治疗(RRT)的时机仍不清楚。
确定重症 AKI 患者中早期开始 RRT 是否降低 90 天全因死亡率。
设计、地点和参与者:这是一项单中心随机临床试验,纳入了 2013 年 8 月至 2015 年 6 月期间德国一家大学医院的 231 例 AKI 符合肾脏疾病:改善全球结局(KDIGO)第 2 阶段(≥基线的 2 倍或尿输出量<0.5 mL/kg/h 持续 12 小时)且血清单核细胞明胶酶相关脂质运载蛋白水平高于 150ng/mL 的重症患者。
早期(在诊断为 KDIGO 第 2 阶段后 8 小时内;n=112)或延迟(在 AKI 第 3 阶段或不开始 RRT 后 12 小时内;n=119)开始 RRT。
主要终点是随机分组后 90 天的死亡率。次要结局包括 28 天和 60 天死亡率、器官功能障碍的临床证据、肾功能恢复、第 90 天后需要 RRT、肾脏支持的持续时间以及重症监护病房(ICU)和住院时间。
在 231 例患者(平均年龄 67 岁;男性 146 例[63.2%])中,早期组(n=112)的所有患者和延迟组(n=119)的 108 例患者(90.8%)均接受了 RRT。所有患者在 90 天均完成随访。早期组从符合全部入选标准到开始 RRT 的中位时间(Q1,Q3)显著短于延迟组(6.0 小时[Q1,Q3:4.0,7.0] vs 25.5 小时[Q1,Q3:18.8,40.3];差异,-21.0[95%CI,-24.0 至-18.0];P<0.001)。与延迟开始 RRT 相比,早期开始 RRT 显著降低 90 天死亡率(44 例[39.3%] vs 65 例[54.7%];危险比[HR],0.66[95%CI,0.45 至 0.97];差异,-15.4%[95%CI,-28.1% 至-2.6%];P=0.03)。早期组有更多的患者在第 90 天恢复肾功能(早期组 60 例[53.6%] vs 延迟组 46 例[38.7%];优势比[OR],0.55[95%CI,0.32 至 0.93];差异,14.9%[95%CI,2.2% 至 27.6%];P=0.02)。与延迟组相比,早期组的 RRT 持续时间和住院时间明显更短(RRT:早期组 9 天[Q1,Q3:4,44] vs 延迟组 25 天[Q1,Q3:7,>90];P=0.04;HR,0.69[95%CI,0.48 至 1.00];差异,-18 天[95%CI,-41 至-4];住院时间:早期组 51 天[Q1,Q3:31,74] vs 延迟组 82 天[Q1,Q3:67,>90];P<0.001;HR,0.34[95%CI,0.22 至 0.52];差异,-37 天[95%CI,-∞ 至-19.5]),但对第 90 天后的 RRT 需求、器官功能障碍和 ICU 住院时间没有显著影响。
在重症 AKI 患者中,与延迟开始 RRT 相比,早期开始 RRT 可降低 90 天内的死亡率。需要进一步开展该干预措施的多中心试验。
德国临床试验注册中心标识符:DRKS00004367。